Mandeep Singh Dhingra, MD is currently the Director and Head of R&D programs at CEPI (Coalition of Epidemic Preparedness Innovations). In this role he is responsible for overseeing scientific decision making and strategic direction setting across all the vaccine development and viral family programs that CEPI is currently supporting. Mandeep completed his medical training from India and was involved in active patient care and academics in India prior to joining the vaccine industry as a part of R&D.
Mandeep has more than 19 years of vaccine industry experience having worked in various roles in Clinical Development, R&D Strategy, Project Leadership, Pharmacovigilance, Clinical QA, Regulatory Affairs, and Medical Affairs initially at Shantha Biotechnics Limited in India and then within the Sanofi US vaccines group. Mandeep has worked on a variety of bacterial and viral vaccines (including novel and first in class vaccines) globally and across the complete development lifecycle of the vaccine (pre-clinical to launch) in LMIC and HIC settings. He has actively collaborated with a variety of national and supranational agencies plus Industry partners to lead and oversee the development of vaccines which are currently licensed globally and being used in routine and outbreak settings. Mandeep has also completed additional training in Business Management and Leadership at the Stanford University School of Business.
4 x speaker presentations, 15 minutes each:
1. Overview of broadly protective vaccines for pandemic prevention: A CIDRAP representative on: 1) the limitations of exclusively reactive vaccine development, 2) the value of defining explicit public health use cases to inform vaccine development, and 3) a brief overview of the various use cases applicable to vaccines for pandemic prevention. 2. Vaccine development and preparedness: A CEPI representative (e.g., Nadia Cohen, Adam Hacker, Mandeep Singh Dhingra) on broadly protective vaccines and how the various use cases can complement CEPI’s 100 Days Mission.3. Broadly protective vaccine feasibility: Florian Krammer, Rebecca Cox, Pamela Bjorkman, or a comparable virologist on what degree of breadth and protection is technically achievable vs. what is needed, using influenza and/or coronavirus vaccines as examples.4. Epidemiology, modeling, and deployment: Charles Whittaker, Asra Ghani, Ros Hollingsworth, Jane True, Lin-Fa Wang, or a comparable expert on when vaccination could prevent spillover, outbreak growth, transmission, and severe disease, as well as the potential impact of vaccine hesitancy, especially as it relates to MRNA platforms.
Additionally Proposed Speakers:CIDRAP RepresentativeCEPI Representative - Nadia Cohen, Adam Hacker, Mandeep Singh DhingraVirologist - Florian Krammer, Rebecca Cox, Pamela Bjorkman